Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

404
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
404
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

1.0K
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
1.0K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

960
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
960
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

552
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
552
Urodynamic Studies: Uroflowmetry01:19

Urodynamic Studies: Uroflowmetry

9.4K
Uroflowmetry is a non-invasive urodynamic test designed to measure various aspects of urination, including volume, flow rate, and the time to void. This test is crucial for diagnosing and assessing conditions such as bladder outlet obstruction, bladder dysfunction, incomplete bladder emptying, incontinence, and urinary tract blockages caused by benign prostatic hyperplasia (BPH) and urethral strictures.Pre-Test Instructions:Before a uroflowmetry test, patients are typically advised to drink...
9.4K
Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

598
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
598

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Duplication of superoxide dismutase and a mutation in aquaglyceroporin mediates the sensitivity of <i>Plasmodium falciparum</i> to cryptosporin, a natural product derived from <i>Acaromyces ingoldii</i>.

bioRxiv : the preprint server for biology·2026
Same author

Evolving landscape of drug development for pediatric rare diseases-from successes to strategies for addressing unmet needs.

Journal of pharmaceutical sciences·2026
Same author

Correlation Between Renal Biomarkers, Glomerular Filtration Rate, and Meropenem Clearance in Pediatric Septic Shock.

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG·2026
Same author

Short-Term Effect of Fast Forceful Abdominal Breathing Yoga in Eyes with Glaucoma.

Ophthalmology. Glaucoma·2026
Same author

Sponsor Initiated Requests to Delay Pediatric Postmarketing Studies.

Pharmaceutical medicine·2026
Same author

Selectivity of OATs and OATPs for Endogenous Metabolites and Signaling Molecules <i>In Vivo</i>.

ACS omega·2026

Related Experiment Video

Updated: Apr 28, 2026

Evaluation of Biomaterials for Bladder Augmentation using Cystometric Analyses in Various Rodent Models
10:19

Evaluation of Biomaterials for Bladder Augmentation using Cystometric Analyses in Various Rodent Models

Published on: August 9, 2012

21.0K

Drug development for pediatric neurogenic bladder dysfunction: dosing, endpoints, and study design.

Jeremiah D Momper1, Alyson Karesh, Dionna J Green

  • 1Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, CA.

Journal of Clinical Pharmacology
|June 13, 2014
PubMed
Summary

Pediatric drug development for neurogenic bladder dysfunction (NBD) faces challenges. Future trials require careful dose testing and meaningful endpoints for successful pediatric NBD treatments.

Keywords:
clinical trial designneurogenic bladderpediatric urologypharmacokinetics

More Related Videos

Detrusor Underactivity Model in Rats by Conus Medullaris Transection
03:26

Detrusor Underactivity Model in Rats by Conus Medullaris Transection

Published on: August 28, 2020

1.5K
The Use of Cystometry in Small Rodents: A Study of Bladder Chemosensation
08:08

The Use of Cystometry in Small Rodents: A Study of Bladder Chemosensation

Published on: August 21, 2012

23.0K

Related Experiment Videos

Last Updated: Apr 28, 2026

Evaluation of Biomaterials for Bladder Augmentation using Cystometric Analyses in Various Rodent Models
10:19

Evaluation of Biomaterials for Bladder Augmentation using Cystometric Analyses in Various Rodent Models

Published on: August 9, 2012

21.0K
Detrusor Underactivity Model in Rats by Conus Medullaris Transection
03:26

Detrusor Underactivity Model in Rats by Conus Medullaris Transection

Published on: August 28, 2020

1.5K
The Use of Cystometry in Small Rodents: A Study of Bladder Chemosensation
08:08

The Use of Cystometry in Small Rodents: A Study of Bladder Chemosensation

Published on: August 21, 2012

23.0K

Area of Science:

  • Pediatric Pharmacology
  • Clinical Trial Design
  • Urology

Background:

  • Pediatric drug development is complex, especially for diseases with different pediatric pathophysiology.
  • Neurogenic bladder dysfunction (NBD) in children has seen multiple failed drug development programs.
  • Evaluating past trial designs is crucial for improving future pediatric NBD therapeutics.

Purpose of the Study:

  • To critically assess clinical trial design elements contributing to unsuccessful pediatric NBD drug development.
  • To identify key factors hindering efficacy demonstration in pediatric NBD drug trials.

Main Methods:

  • Reviewed trial designs of drugs tested for pediatric NBD using FDA submissions.
  • Extracted data on trial design, endpoints, eligibility, and pharmacokinetics from FDA reviews.
  • Analyzed four drug development programs for pediatric NBD.

Main Results:

  • Only one of the four evaluated drugs (oxybutynin) demonstrated efficacy in pediatric NBD.
  • Identified common issues in trial design across unsuccessful programs.
  • Programs provided some clinically useful information despite lack of efficacy.

Conclusions:

  • Future pediatric NBD trials need rigorous dose-ranging studies.
  • Objective, clinically meaningful endpoints are essential for pediatric drug development.
  • Interpretable and feasible clinical trial designs are critical for success in pediatric NBD treatment development.